Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action

Br J Pharmacol. 2011 Jul;163(5):912-26. doi: 10.1111/j.1476-5381.2011.01254.x.

Abstract

Background and purpose: The two longest C-termini of the purinergic P2X receptors occur in the P2X2 and P2X7 receptors and are thought to interact with multiple cytoplasmic proteins, among which are members of the cytoskeleton, including microtubules. In this work we asked whether disrupting the microtubule cytoskeleton might affect the functions of these receptors.

Experimental approach: Functions of heterologously expressed P2X2 and P2X7 receptors were evaluated with electrophysiology and dye uptake following ATP application. Permeabilization and secretion of pro-inflammatory agents were quantified from fresh or cultured peritoneal mouse macrophages, treated in vitro or in vivo with colchicine.

Key results: Disrupting the microtubule network with colchicine did not affect currents generated by ATP in P2X2 and P2X7 receptor-expressing cells but inhibited uptake of the dye Yo-Pro-1 in Xenopus oocytes and HEK293 cells expressing these channels. Peritoneal mouse macrophages showed less ATP-induced permeabilization to ethidium bromide in the presence of colchicine, and less reactive oxygen species (ROS) formation, nitric oxide (NO) and interleukin (IL)-1β release. Colchicine treatment did not affect ATP-evoked currents in macrophages. Finally, in vivo assays with mice inoculated with lipopolysaccharide and ATP showed diminished ROS, IL-1β, interferon-γ and NO production after colchicine treatment.

Conclusions and implications: Colchicine has known anti-inflammatory actions and is used to treat several conditions involving innate immunity, including gout and familial Mediterranean fever. Here we propose a new mechanism of action - inhibition of pore formation induced by activation of P2X receptors - which could explain some of the anti-inflammatory effects of colchicine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism*
  • Adenosine Triphosphate / pharmacology
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Cell Death / drug effects
  • Colchicine / pharmacology*
  • Colchicine / therapeutic use
  • Cytoskeleton / drug effects
  • Cytoskeleton / ultrastructure
  • Female
  • Fluorescent Dyes / pharmacokinetics
  • HEK293 Cells
  • Humans
  • Interferon-gamma / metabolism
  • Interleukin-1beta / metabolism
  • Ion Channel Gating / drug effects*
  • Lipopolysaccharides / pharmacology
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / ultrastructure
  • Male
  • Mice
  • Microscopy, Fluorescence
  • Microtubules / drug effects
  • Microtubules / ultrastructure
  • Nitric Oxide / metabolism
  • Oocytes / drug effects
  • Oocytes / metabolism
  • Oocytes / ultrastructure
  • Rats
  • Reactive Oxygen Species / metabolism
  • Receptors, Purinergic P2X2 / genetics
  • Receptors, Purinergic P2X2 / physiology*
  • Receptors, Purinergic P2X7 / genetics
  • Receptors, Purinergic P2X7 / physiology*
  • Transfection
  • Xenopus laevis

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Fluorescent Dyes
  • Interleukin-1beta
  • Lipopolysaccharides
  • Reactive Oxygen Species
  • Receptors, Purinergic P2X2
  • Receptors, Purinergic P2X7
  • Nitric Oxide
  • Interferon-gamma
  • Adenosine Triphosphate
  • Colchicine